Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Chief Development Officer | November 05, 2025 | November 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date November 05, 2025 · Filed November 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,657 |
Ending reported balance
After 2025-11-06 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2025-11-05 · Exercise / conversion · Acquired 800 · Balance 60,457 Row 2 · 2025-11-05 · Sale · Disposed 800 · Balance 59,657 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.05 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Row 3 · 2025-11-05 · Exercise / conversion · Acquired 801 · Balance 60,458 Row 4 · 2025-11-05 · Sale · Disposed 801 · Balance 59,657 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.05 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Row 5 · 2025-11-06 · Exercise / conversion · Acquired 14,738 · Balance 74,395 Row 6 · 2025-11-06 · Sale · Disposed 14,738 · Balance 59,657 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.84 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Row 7 · 2025-11-06 · Exercise / conversion · Acquired 18,300 · Balance 77,957 Row 8 · 2025-11-06 · Sale · Disposed 18,300 · Balance 59,657 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.84 to $76.65 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.78 · Expires 2028-01-03 | Direct | 14,738 |
Reported balance
After 2025-11-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-11-05 · Exercise / conversion · Disposed 800 · Balance 14,738 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.78 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2025-11-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-11-06 · Exercise / conversion · Disposed 14,738 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.89 · Expires 2027-01-01 | Direct | 18,300 |
Reported balance
After 2025-11-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-11-05 · Exercise / conversion · Disposed 801 · Balance 18,300 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.89 · Expires 2027-01-01 | Direct | 0 |
Reported balance
After 2025-11-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-11-06 · Exercise / conversion · Disposed 18,300 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.05 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.84 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.84 to $76.65 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 18,300 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · derivative · entry 12 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,300 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,738 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · derivative · entry 10 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,738 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 18,300 | $75.42 | $1,380,204.30 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 8 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.84 to $76.65 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 18,300 | $60.89 | $1,114,287.00 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 7 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 14,738 | $76.10 | $1,121,520.53 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 6 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.84 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 14,738 | $56.78 | $836,823.64 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 5 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 801 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · derivative · entry 11 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 801 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · derivative · entry 9 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,738 Underlying: Common Stock · 800 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 801 | $75.01 | $60,083.01 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 4 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.05 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 801 | $60.89 | $48,772.89 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 3 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 800 | $75.01 | $60,008.00 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.05 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 800 | $56.78 | $45,424.00 |
DisclosureSEC source: 0000874015-25-000277 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 905 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · derivative · entry 13 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,971 Underlying: Common Stock · 905 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 775 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · derivative · entry 11 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,668 Underlying: Common Stock · 775 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 905 | $75.05 | $67,923.87 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 9 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 905 | $60.89 | $55,105.45 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 8 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 775 | $75.05 | $58,166.85 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 7 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 775 | $56.78 | $44,004.50 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 6 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 7, 2025 22:12 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 775 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-25-000276 · edgardoc.xml · derivative · entry 6 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,101 Underlying: Common Stock · 775 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4 Read SEC document |
| November 03, 2025 Filed Nov 7, 2025 22:12 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 905 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-25-000276 · edgardoc.xml · derivative · entry 5 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,538 Underlying: Common Stock · 905 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4 Read SEC document |
| November 03, 2025 Filed Nov 7, 2025 22:12 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 905 | $75.05 | $67,923.87 |
DisclosureSEC source: 0000874015-25-000276 · edgardoc.xml · nonDerivative · entry 4 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| November 03, 2025 Filed Nov 7, 2025 22:12 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 905 | $56.78 | $51,385.90 |
DisclosureSEC source: 0000874015-25-000276 · edgardoc.xml · nonDerivative · entry 3 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4 Read SEC document |
| November 03, 2025 Filed Nov 7, 2025 22:12 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 775 | $75.05 | $58,166.85 |
DisclosureSEC source: 0000874015-25-000276 · edgardoc.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| November 03, 2025 Filed Nov 7, 2025 22:12 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 775 | $60.89 | $47,189.75 |
DisclosureSEC source: 0000874015-25-000276 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4 Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 34,585 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · derivative · entry 12 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,876 Underlying: Common Stock · 34,585 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 34,664 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · derivative · entry 10 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,443 Underlying: Common Stock · 34,664 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 20,000 | $75.11 | $1,502,166.00 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 5 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.47 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 34,664 | $75.11 | $2,603,554.11 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 4 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.47 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 34,664 | $56.78 | $1,968,221.92 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 3 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 34,585 | $75.11 | $2,597,620.56 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.47 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 34,585 | $60.89 | $2,105,880.65 |
DisclosureSEC source: 0000874015-25-000270 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 57,900 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-25-000239 · edgardoc.xml · derivative · entry 3 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,900 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 57,900 | $65.24 | $3,777,668.13 |
DisclosureSEC source: 0000874015-25-000239 · edgardoc.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.52 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 57,900 | $53.77 | $3,113,283.00 |
DisclosureSEC source: 0000874015-25-000239 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2025 Filed Sep 5, 2025 00:37 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $50.37 | $503,671.00 |
DisclosureSEC source: 0000874015-25-000218 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,657 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.01 to $50.92, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 22:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 165 | $27.71 | $4,572.15 |
DisclosureSEC source: 0000874015-25-000190 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,657 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 29, 2025. These shares may not be sold until March 2, 2026. Read SEC document |
| August 05, 2025 Filed Aug 6, 2025 22:44 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $42.86 | $428,593.00 |
DisclosureSEC source: 0000874015-25-000174 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,492 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.5 to $42.83 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 415 | $28.21 | $11,707.77 |
DisclosureSEC source: 0000874015-25-000100 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,492 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,406 | $32.40 | $45,561.29 |
DisclosureSEC source: 0000874015-25-000076 · edgardoc.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,077 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.05 to $32.61 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 00:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantCommon Stock | 3,820 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000076 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,483 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the final performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 7,072 | $32.86 | $232,407.14 |
DisclosureSEC source: 0000874015-25-000059 · edgardoc.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,663 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.855 to $32.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 18,901 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000059 · edgardoc.xml · derivative · entry 5 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,724 Underlying: Common Stock · 18,901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 33,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000059 · edgardoc.xml · derivative · entry 4 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,625 Underlying: Common Stock · 33,000 shares Expires not disclosed F6 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 22,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000059 · edgardoc.xml · derivative · entry 3 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,801 Underlying: Common Stock · 22,000 shares Expires not disclosed F4 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F5 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. F5 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 18,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000059 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:00 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $34.69 | $0.00 |
DisclosureSEC source: 0000874015-25-000032 · edgardoc.xml · derivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Grant on 01/02/2025 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| August 30, 2024 Filed Sep 5, 2024 01:41 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 11 | $38.64 | $425.05 |
DisclosureSEC source: 0000874015-24-000217 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,834 F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 30, 2024. These shares may not be sold until February 28, 2025. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 331 | $49.63 | $16,427.53 |
DisclosureSEC source: 0000874015-24-000191 · edgardoc.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,823 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 8, 2024. Read SEC document |
| August 28, 2024 Filed Sep 3, 2024 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 320 | $49.16 | $15,731.20 |
DisclosureSEC source: 0000874015-24-000191 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,154 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 8, 2024. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,430 | $48.00 | $116,640.00 |
DisclosureSEC source: 0000874015-24-000189 · edgardoc.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,508 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 8, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.